dalteparin has been researched along with Systemic Inflammatory Response Syndrome in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Systemic Inflammatory Response Syndrome: A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dalteparin-treated patients received a commencement bolus of 20 units/kg and a maintenance infusion at 10 units/kg/hr." | 2.69 | A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. ( Cumming, AR; Gallagher, L; O'Brien, JL; Reeves, JH; Santamaria, JD, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keskin, H | 1 |
| Keskin, F | 1 |
| Yildirim, E | 1 |
| Saritas, S | 1 |
| Polat, G | 1 |
| Colak, A | 1 |
| Laloglu, F | 1 |
| Guler, MA | 1 |
| Ozay, M | 1 |
| Alp, H | 1 |
| Sochet, AA | 1 |
| Morrison, JM | 1 |
| Jaffray, J | 1 |
| Godiwala, N | 1 |
| Wilson, HP | 1 |
| Thornburg, CD | 1 |
| Bhat, RV | 1 |
| Zia, A | 1 |
| Lawrence, C | 1 |
| Kudchadkar, SR | 1 |
| Hamblin, F | 1 |
| Russell, CJ | 1 |
| Streiff, MB | 1 |
| Spyropoulos, AC | 1 |
| Amankwah, EK | 1 |
| Goldenberg, NA | 1 |
| Anastas, DC | 1 |
| Farias, A | 1 |
| Runyon, J | 1 |
| Laufer, M | 1 |
| Sendi, P | 1 |
| Totapally, B | 1 |
| Sachdeva, R | 1 |
| Reeves, JH | 1 |
| Cumming, AR | 1 |
| Gallagher, L | 1 |
| O'Brien, JL | 1 |
| Santamaria, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial[NCT04354155] | Phase 2 | 40 participants (Actual) | Interventional | 2020-06-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To investigate, on a preliminary basis, the efficacy of in-hospital thromboprophylaxis with twice-daily enoxaparin in children hospitalized with COVID-19, as measured by number of participants with confirmed HA-VTE. (NCT04354155)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Thromboprophylaxis | 2 |
"The safety of in-hospital thromboprophylaxis with twice-daily low-dose enoxaparin thromboprophylaxis will be measured by cumulative incidence (number of participants) of ISTH-defined clinically-relevant bleeding events during hospitalization. Clinically relevant bleeding episodes may include any of the following:~fatal bleeding;~clinically overt bleeding associated with a decline in hemoglobin of ≥2g/dL in a 24h period;~retroperitoneal, pulmonary, or central nervous system bleeding;~bleeding requiring surgical intervention in an operating suite;~bleeding for which a blood product is administered (blood product administration not directly attributable to the patient's underlying condition);~bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating suite." (NCT04354155)
Timeframe: Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Thromboprophylaxis | 0 |
The median twice-daily enoxaparin dose, as measured in mg/kg, required to achieve a 4-hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL in children hospitalized with COVID-19, and to compare dose-requirements by age group (<12 and those >12 years of age). (NCT04354155)
Timeframe: 4 hours post initial dose
| Intervention | mg/kg (Median) | |
|---|---|---|
| Children 12 years or older | Children less than 12 years | |
| Thromboprophylaxis | 0.5 | 0.52 |
2 trials available for dalteparin and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial.
Topics: Anticoagulants; Child; COVID-19; Enoxaparin; Hemorrhage; Humans; Prospective Studies; Systemic Infla | 2022 |
A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration.
Topics: Acute Kidney Injury; Adult; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Hemofiltration; Hemog | 1999 |
2 other studies available for dalteparin and Systemic Inflammatory Response Syndrome
| Article | Year |
|---|---|
Case of Venous Thromboembolia Under Enoxaparin Prophylaxis After Recovering From Acute Ischemic Stroke in Consequence of COVID-19-Related MIS-C.
Topics: Anticoagulants; Brain Ischemia; COVID-19; Enoxaparin; Humans; Ischemic Stroke; Systemic Inflammatory | 2022 |
Massive Pulmonary Embolism in an Adolescent With Multisystem Inflammatory Syndrome Due to COVID-19.
Topics: Adolescent; Computed Tomography Angiography; COVID-19; Enoxaparin; Female; Fibrinolytic Agents; Huma | 2021 |